Trial Profile

First-in-human Phase 1 single ascending dose study assessing ART2612

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ART26.12 (Primary)
Indications Chemotherapy-induced damage; Peripheral neuropathies
Focus Adverse reactions; First in man

Most Recent Events

29 Jun 2026 According to Artelo Biosciences media release, data from this trial will be presented at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium.
29 Jun 2026 Results presented in the Artelo Biosciences media release.
10 Jun 2026 According to Artelo Biosciences media release, data from the study were presented at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com